Stephen J Mehler1, Lauren R May2, Crystal King3, William S Harris4, Zubin Shah5. 1. Hope Veterinary Specialists, Malvern, PA 19355, United States; Veterinarian Recommended Solutions, 502 West Germantown Pike, Suite 610, Plymouth Meeting, PA 19462, United States. Electronic address: smehler@vrshealth.com. 2. Hope Veterinary Specialists, Malvern, PA 19355, United States. 3. Veterinarian Recommended Solutions, 502 West Germantown Pike, Suite 610, Plymouth Meeting, PA 19462, United States. 4. The Department of Internal Medicine, Sanford School of Medicine, University of South Dakota and OmegaQuant Analytics, LLC, Sioux Falls, SD, United States. 5. New York Institute of Technology - College of Osteopathic Medicine, Old Westbury, NY 11568, United States.
Abstract
BACKGROUND: Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treatment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiflammatory pharmaceuticals. Omega-3 (n-3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in dogs. OBJECTIVE: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of supplementation on the arachadonic acid (ARA)/ (EPA+DHA) algorithm and 3) to correlate alterations in the ARA/(EPA+DHA) with changes in the clinical signs of canine OA. METHODS: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind, placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an average dose of 69mg EPA+DHA/kg/day). Orthopedic examinations and blood analyses were performed at baseline, day 42, and day 84. A single investigator confirmed a diagnosis of OA of the coxofemoral joints and/or stifle joints in all dogs. RESULTS: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness, and joint severity at day 84 and all blood metrics at day 42 and day 84 significantly (p<0.05) improved compared with placebo. No major side effects were observed. CONCLUSION AND CLINICAL RELEVANCE: This study demonstrated that the daily supplementation of a dogs diet with EPA and DHA shifts the blood fatty acid concentrations correlating to relief of clinical signs associated with OA in dogs.
BACKGROUND:Osteoarthritis (OA) in dogs is a prevalent and serious condition. The most common treatment for the clinical signs of OA in dogs is the administration of nonsteroidal antiiflammatory pharmaceuticals. Omega-3 (n-3) fatty acids have been shown to reduce the clinical signs of osteoarthritis in dogs. OBJECTIVE: The primary goals of this study were 1) to determine the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the clinical signs of OA in dogs, 2) to evaluate the effects of supplementation on the arachadonic acid (ARA)/ (EPA+DHA) algorithm and 3) to correlate alterations in the ARA/(EPA+DHA) with changes in the clinical signs of canine OA. METHODS: Seventy-eight client owned dogs were enrolled in a prospective, randomized, double-blind, placebo controlled clinical trial. Dogs were randomized to placebo oil or triglyceride n-3 oil (providing an average dose of 69mg EPA+DHA/kg/day). Orthopedic examinations and blood analyses were performed at baseline, day 42, and day 84. A single investigator confirmed a diagnosis of OA of the coxofemoral joints and/or stifle joints in all dogs. RESULTS: Seventy-four dogs completed the trial. All clinical outcomes for measuring discomfort, lameness, and joint severity at day 84 and all blood metrics at day 42 and day 84 significantly (p<0.05) improved compared with placebo. No major side effects were observed. CONCLUSION AND CLINICAL RELEVANCE: This study demonstrated that the daily supplementation of a dogs diet with EPA and DHA shifts the blood fatty acid concentrations correlating to relief of clinical signs associated with OA in dogs.
Authors: Conny Mosley; Tara Edwards; Laura Romano; Geoffrey Truchetti; Laurie Dunbar; Teresa Schiller; Tom Gibson; Charles Bruce; Eric Troncy Journal: Front Vet Sci Date: 2022-04-26
Authors: Sara Casati; Chiara Giannasi; Stefania Niada; Elena Della Morte; Marica Orioli; Anna T Brini Journal: Stem Cells Transl Med Date: 2022-09-21 Impact factor: 7.655